Factor VIII F8 Antibodies
Affinity Biologicals, Inc. manufactures a broad range of Factor VIII F8 Antibodies which can be found in the listing below. Further information about each individual Factor VIII antibody is available by following the associated links. Our Factor VIII F8 Antibodies are excellent for use in immunoassays where high sensitivity is required and are frequently the preferred reagent for immunopreciptaion techniques and activity neutralization assays. These antibodies have proven to be extremely useful in the preparation of immune-adsorbent resins for use in immuno-depletion of specific proteins from plasma as well as immuno-affinity purification of proteins. Affinity’s Factor VIII F8 Antibodies are manufactured for use in research applications.
Listing of Factor VIII F8 Antibodies
SAF8C-IG – Sheep anti human Factor VIII, purified IgG (10mg vial)
SAC8C-IG – Sheep anti Canine Factor VIII, purified IgG (5mg vial)
SAC8C-HRP – Sheep anti-canine Factor VIII:C,peroxidase conjugated IgG (0.2 mg vial)
SAF8C-APBIO – Sheep anti human Factor VIII:C, affinity purified, Biotinylated IgG (0.1 mg vial)
SAF8C-HRP – Sheep anti human Factor VIII:C, peroxidase conjugated IgG (0.2 mg vial)
SAF8C-APFTC – Sheep anti human Factor VIII:C, affinity purified, FITC conjugated IgG (0.1 mg vial)
SAF8C-AP – Sheep anti human Factor VIII:C, affinity purified IgG (0.5 mg vial)
F8C-EIA – Factor VIII:C Paired Antibody Set – 4 plate set
CFVIII-EIA –Canine Factor VIII Paired Antibody Set – 4 plate set
FVIII-AG – Complete Factor VIII Antigen ELISA Kit – 1 plate/kit
Description of Factor VIII (FVIII)
Factor VIII (formerly referred to as antihemophilic globulin and Factor VIII:C) is a large glycoprotein (320 kDa) that circulates in plasma at approximately 200 ng/ml. Synthesized in the liver, the majority of Factor VIII is cleaved during expression, resulting in a heterogeneous mixture of partially cleaved forms of FVIII ranging in size from 200-280 kDa. The FVIII is stabilized by association with von Willebrand Factor to form a FVIII-vWF complex required for the normal survival of FVIII in vivo (t1/2 of 8-12 hours).
F.VIII is a pro-cofactor that is activated through limited proteolysis by thrombin. In this process F.VIIIa dissociates from vWF to combine with activated Factor IX, calcium and a phospholipid surface where it is an essential cofactor in the assembly of the Factor X activator complex. Once dissociated from vWF, FVIIIa is susceptible to inactivation by activated Protein C and by non-enzymatic decay.
Hemophilia A is a congenital bleeding disorder resulting from an X-chromosome-linked deficiency of FVIII. The severity of the deficiency generally correlates with the severity of the disease. Some Hemophiliacs (~10%) produce a FVIII protein that is partially or totally inactive. The production of neutralizing antibodies to FVIII also occurs in 5-20% of Hemophiliacs 1-3.
References and Reviews
- Lollar P, Fay PJ, Fass DN; Factor VIII and Factor VIIIa. Methods in Enzymology, 222, pg 122, 1993.
- Hoyer, LW, Wyshock EG, Colman RW, in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 109-133, J.B. Lippincott Co., Philadelphia, 1994.
- Pittman DD, Kaufman RJ. Structure-Function Relationships of Factor VIII Elucidated through Recombinant DNA Technology. Thromb. Haemostas. 61:161-165, 1989.